We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+21.94%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$53.3M
Cap. Flow
+$23M
Cap. Flow %
4.23%
Top 10 Hldgs %
49.87%
Holding
88
New
19
Increased
18
Reduced
25
Closed
23

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$13M
2
SRRK icon
Scholar Rock
SRRK
+$10.7M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.4M
4
PCVX icon
Vaxcyte
PCVX
+$9.43M
5
PFE icon
Pfizer
PFE
+$8.03M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$14.9M
2
VRNA
Verona Pharma
VRNA
+$13.9M
3
IRON icon
Disc Medicine
IRON
+$11.7M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$9.97M
5
WVE icon
Wave Life Sciences
WVE
+$8.49M

Sector Composition

Rank Sector Weight
1 Healthcare 90.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
76
Kura Oncology
KURA
$793M
– –
-581,369
Closed -$3.84M
LQDA icon
77
Liquidia Corp
LQDA
$7.72B
– –
-214,057
Closed -$3.16M
MDGL icon
78
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-10,344
Closed -$3.43M
OCUL icon
79
Ocular Therapeutix
OCUL
$1.83B
– –
-551,570
Closed -$4.04M
PTCT icon
80
PTC Therapeutics
PTCT
$6.18B
– –
-60,389
Closed -$3.08M
SLDB icon
81
Solid Biosciences
SLDB
$792M
– –
-452,239
Closed -$1.67M
SLNO
82
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-42,500
Closed -$3.04M
TARS icon
83
Tarsus Pharmaceuticals
TARS
$2.55B
– –
-81,331
Closed -$4.18M
TVTX icon
84
Travere Therapeutics
TVTX
$5.17B
– –
-408,849
Closed -$7.33M
UNCY icon
85
Unicycive Therapeutics
UNCY
$130M
– –
-241,349
Closed -$1.39M
VXRT
86
DELISTED
Vaxart
VXRT
– –
-683,825
Closed -$278K
WVE icon
87
Wave Life Sciences
WVE
$1.12B
– –
-1,050,374
Closed -$8.49M
XENE icon
88
Xenon Pharmaceuticals
XENE
$6.1B
– –
-10,121
Closed -$340K
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Silverarc Capital Management held 88 positions worth $542M, up 11% from $489M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management deployed $23M of net new capital in Q2 2025, opening 19 new positions and adding to 18 existing holdings. Its largest new stake was CG Oncology: 541,034 shares worth $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $14.9M trimmed.

  • Silverarc Capital Management's largest Q2 2025 buy was CG Oncology: 541,034 shares worth $14.1M.
  • Silverarc Capital Management added most to Neurocrine Biosciences in Q2 2025, an estimated $10.4M increase.
  • Silverarc Capital Management's biggest Q2 2025 reduction was Nuvalent, cutting an estimated $14.9M.
  • Silverarc Capital Management fully exited Disc Medicine in Q2 2025, selling an estimated $11.7M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $542M portfolio in Q2 2025.
  • Silverarc Capital Management opened 19 new positions and closed 23 in Q2 2025.
  • Silverarc Capital Management's portfolio value rose 11% quarter-over-quarter to $542M.

Based on Silverarc Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.